MIVSET Trademark
Trademark Overview
On Thursday, November 20, 2025, a trademark application was filed for MIVSET with the United States Patent and Trademark Office. The USPTO has given the MIVSET trademark a serial number of 99507779. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, May 26, 2026. This trademark is owned by Kyverna Therapeutics, Inc.. The MIVSET trademark is filed in the Pharmaceutical Products category with the following description:
Therapeutic pharmaceuticals for the treatment of autoimmune diseases; therapeutic pharmaceuticals and cell therapy products in the nature of cells for medical or clinical use for the treatment of autoimmune disease; cell therapy products, namely, genetically engineered immune cells for medical or clinical use for the treatment of autoimmune disease; pharmaceutical preparations and substances for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders
General Information
| Serial Number | 99507779 |
| Word Mark | MIVSET |
| Filing Date | Thursday, November 20, 2025 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, May 26, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 26, 2026 |
Trademark Statements
| Goods and Services | Therapeutic pharmaceuticals for the treatment of autoimmune diseases; therapeutic pharmaceuticals and cell therapy products in the nature of cells for medical or clinical use for the treatment of autoimmune disease; cell therapy products, namely, genetically engineered immune cells for medical or clinical use for the treatment of autoimmune disease; pharmaceutical preparations and substances for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, November 20, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Kyverna Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Emeryville, CA 94608
US |
| Party Name | Kyverna Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Emeryville, CA 94608
US |
Trademark Events
| Event Date | Event Description |
| Thursday, November 20, 2025 | NEW APPLICATION ENTERED |
| Thursday, November 20, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, November 20, 2025 | APPLICATION FILING RECEIPT MAILED |
| Thursday, March 26, 2026 | ASSIGNED TO EXAMINER |
| Thursday, March 26, 2026 | NON-FINAL ACTION WRITTEN |
| Thursday, March 26, 2026 | NON-FINAL ACTION E-MAILED |
| Thursday, March 26, 2026 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, April 29, 2026 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, April 29, 2026 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, April 29, 2026 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, April 29, 2026 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, April 29, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, May 20, 2026 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, May 26, 2026 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 26, 2026 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
